Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses

Omata, Wataru; Tsutsumida, Arata; Namikawa, Kenjiro; Takahashi, Akiko; Oashi, Kohei; Yamazaki, Naoya

doi:10.4137/ccrep.s39851

Cited by 7 publications

(9 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pathologically, these manifestations are often identified as COP, as seen in patients 1, 5, and 6 and represent the most common pathologic finding seen in the pulmonary parenchyma [ 3 , 7 ]. Other pathologies reported include necrobiotic nodules (sterile accumulations of neutrophils in an area of necrosis) or granulomatous inflammation as seen in patients 1, 2, 3, and 4 [ 3 , 8 ]. Others have reported usual interstitial pneumonia, lymphocytic interstitial pneumonia, desquamative interstitial pneumonia, and eosinophilic interstitial pneumonia [ 2 , 3 , 4 ].…”

Section: Discussionmentioning

confidence: 99%

Pulmonary Manifestations of Inflammatory Bowel Disease in Children

Taylor

Zhou

Dansie

et al. 2020

Cureus

View full text Add to dashboard Cite

The recognition of pulmonary manifestations of inflammatory bowel disease (IBD) is important as these diseases can be confused with infectious etiologies (e.g., tuberculosis or fungal infection) and, as a result, may unnecessarily delay institution of appropriate therapy (e.g., infliximab). Furthermore, they are a source of morbidity that may be overlooked and, like other IBD-related pathologies, are often responsive to treatment with corticosteroids, immunomodulators, or biologic therapies. The purpose of this paper is to describe the cases of six children at a single institution with differing presentations, treatments, and responses to treatment of their IBD-related lung disease to improve recognition of this uncommon process.

show abstract

Section: Discussionmentioning

confidence: 99%

Pulmonary Manifestations of Inflammatory Bowel Disease in Children

Taylor

Zhou

Dansie

et al. 2020

Cureus

View full text Add to dashboard Cite

show abstract

“…In addition, deep venous aneurysms can also present with deep venous thrombosis or pulmonary embolism [ 3 ]. The clinical differential diagnosis for a venous aneurysm includes benign adipose, melanocytic and vascular lesions (Table 1 ) [ 4 - 12 ].…”

Section: Discussionmentioning

confidence: 99%

Spontaneous Venous Aneurysm: Report of a Non-traumatic Superficial Venous Aneurysm on the Distal Arm

McKesey

Cohen

2018

Cureus

View full text Add to dashboard Cite

Venous aneurysms are benign acquired vascular lesions. A 59-year-old man developed a lesion on his right wrist that would enlarge and flatten depending on whether his arm was dependent or elevated; he had no prior history of trauma to the site. Examination of his wrist revealed a soft, compressible nodule contiguous with venous structures in the area. The history and clinical appearance established the diagnosis of a superficial venous aneurysm. Venous aneurysms typically occur on extremities, either in the superficial or deep venous systems; a prior history of trauma is often elicited. Clinical observation may be appropriate for the management of venous aneurysms; however, symptomatic lesions often require excision. In conclusion, venous aneurysms often appear in adults; trauma may or may not precede their appearance. Asymptomatic lesions may be observed, whereas surgery may be necessary to resolve the condition if the aneurysm is symptomatic.

show abstract

“…The results of this study indicate an ORR of 14.3% and an OS of 12.5 months, suggesting this treatment plan has a slight improvement over the traditional prognosis when patients are given DTIC as a single-agent (a typical OS of 9.2 months is seen in metastatic mucosal melanoma patients). 94 However, the safety profile of this combination demonstrated some toxicity as 28.6% of patients had a grade 3 or 4 AE such as leukocytopenia and neutropenia. 94 Other chemotherapies.…”

Section: Combination Therapiesmentioning

confidence: 99%

“…94 However, the safety profile of this combination demonstrated some toxicity as 28.6% of patients had a grade 3 or 4 AE such as leukocytopenia and neutropenia. 94 Other chemotherapies. In 2011, a phase II trial was conducted evaluating the combination of nab-paclitaxel with carboplatin (P + CB) against chemotherapy naïve (CN) or previously treated (PT) patients with unresectable stage IV melanoma.…”

Section: Combination Therapiesmentioning

confidence: 99%

“… 93 In a real-world retrospective analysis, this combination was looked at in a sequential application against metastatic mucosal melanoma of the sinuses. 94 The study was designed where a combination of C + P was given sequentially after DTIC administration to 7 patients. The results of this study indicate an ORR of 14.3% and an OS of 12.5 months, suggesting this treatment plan has a slight improvement over the traditional prognosis when patients are given DTIC as a single-agent (a typical OS of 9.2 months is seen in metastatic mucosal melanoma patients).…”

Section: Combination Therapiesmentioning

confidence: 99%

See 1 more Smart Citation

Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma

2021

View full text Add to dashboard Cite

Melanoma is the deadliest form of skin cancer in the world with a growing incidence in North America. Contemporary treatments for melanoma include surgical resection, chemotherapy, and radiotherapy. However, apart from resection in early melanoma, the prognosis of patients using these treatments is typically poor. In the past decade, there have been significant advancements in melanoma therapies. Immunotherapies such as ipilimumab and targeted therapies such as vemurafenib have emerged as a promising option for patients as seen in both scientific and clinical research. Furthermore, combination therapies are starting to be administered in the form of polychemotherapy, polyimmunotherapy, and biochemotherapy, of which some have shown promising outcomes in relative efficacy and safety due to their multiple targets. Alongside these treatments, new research has been conducted into the evidence-based use of natural health products (NHPs) and natural compounds (NCs) on melanoma which may provide a long-term and non-toxic form of complementary therapy. Nevertheless, there is a limited consolidation of the research conducted in emerging melanoma treatments which may be useful for researchers and clinicians. Thus, this review attempts to evaluate the therapeutic efficacy of current advancements in metastatic melanoma treatment by surveying new research into the molecular and cellular basis of treatments along with their clinical efficacy. In addition, this review aims to elucidate novel strategies that are currently being used and have the potential to be used in the future.

show abstract

Sequential Combination Chemotherapy of Dacarbazine (DTIC) with Carboplatin and Paclitaxel for Patients with Metastatic Mucosal Melanoma of Nasal Cavity and Paranasal Sinuses

Cited by 7 publications

References 35 publications

Pulmonary Manifestations of Inflammatory Bowel Disease in Children

Pulmonary Manifestations of Inflammatory Bowel Disease in Children

Spontaneous Venous Aneurysm: Report of a Non-traumatic Superficial Venous Aneurysm on the Distal Arm

Current Advancements and Novel Strategies in the Treatment of Metastatic Melanoma

Contact Info

Product

Resources

About